Barr warfarin lobbying support costs company $1.5 mil. in fourth quarter.
BARR SPENT $1.5 MIL. IN WARFARIN-RELATED LOBBYING IN 4TH QUARTER, contributing to a drop in net earnings from $1.7 mil. for the three months ending June 30, 1996 to $527,000 for the equivalent period in 1997, the firm said. Barr's lobbying expenses accounted for more than half of the $2.5 mil. spent on warfarin in the fourth quarter.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth